Risk of Stroke With Various Types of Menopausal Hormone Therapies: A National Cohort Study

@article{Lkkegaard2017RiskOS,
  title={Risk of Stroke With Various Types of Menopausal Hormone Therapies: A National Cohort Study},
  author={Ellen Christine Leth L{\o}kkegaard and Lars Hougaard Nielsen and Niels Keiding},
  journal={Stroke},
  year={2017},
  volume={48},
  pages={2266–2269}
}
Background and Purpose— Double-blind randomized studies on the effects of oral postmenopausal hormone therapies were stopped mainly because of increased risk of stroke. We aimed to assess the risk of all strokes and various subtypes associated with hormone therapy and explore the influence of regimens and routes of administration. Methods— A national historical cohort of women aged 51 to 70 years from 1995 to 2010 was established by linking 5 Danish registries. The National Registry of… 

Figures from this paper

Conjugated equine estrogen used in postmenopausal women associated with a higher risk of stroke than estradiol
This study aimed to evaluate the risk of ischemic stroke (IS) in hormone therapy (HT) with oral conjugated equine estrogen (CEE) and estradiol (E2) in postmenopausal women in Taiwan. A retrospective
Women on Hormone Therapy with Ischemic Stroke, Effects on Deficits and Recovery
TLDR
While cautions persist on the use, route and dosage of HT for risks of ischemic stroke, the HT moderation of AIS deficits and outcomes in women <80 years of age warrants further investigation.
The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review
TLDR
Use of low-dose oral and transdermal HT appears to be safe with regard to CVD risk in women in menopausal transition and within the first years after menopause onset, andTransdermal estrogen with <50 μg/day of estrogen combined with micronized progesterone seems to be the safer choice with respect to thrombotic and stroke risk.
A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases
TLDR
Differential clinical effects depending on timing of initiation, underlying disease, regimen type, and route of administration were identified through subgroup analyses, suggesting that underlying disease and timing of initiated therapy in postmenopausal women should be carefully considered.
Hormone therapy for first-line management of menopausal symptoms: Practical recommendations
TLDR
A brief historical perspective of events that led to the backlash against hormone therapy is provided, the current position of guideline groups is explored, and practical recommendations to guide first-line management of symptomatic menopausal women are provided.
Drugs Associated With Ischemic Stroke
Supplemental Digital Content is available in the text. Certain drugs may increase the risk of ischemic stroke (IS). Our goal was to review associations between frequently used drugs and IS. We
Vaginal estrogen use and chronic disease risk in the Nurses' Health Study.
TLDR
The findings lend support to the safety of vaginal estrogen use, a highly effective treatment for genitourinary syndrome of menopause, by suggesting that risks for cardiovascular disease, cancer, and hip fracture were not different between users and nonusers of vaginal testosterone.
Gender‐specific therapeutic approach in arterial hypertension – Challenges ahead
Prevalence of the Use of Oral Contraceptives and Hormone Replacement Therapy in Japan: The Japan Nurses’ Health Study
TLDR
The information obtained in this study will be useful for clarification of the association between exogenous estrogen exposure and estrogen-related diseases as future research.
...
1
2
3
...

References

SHOWING 1-10 OF 11 REFERENCES
Increased risk of stroke in hypertensive women using hormone therapy: analyses based on the Danish Nurse Study.
TLDR
The present study finds an increased risk of stroke among hypertensive but not normotensive women using HT, and suggests that HT should be avoided in hypertensive women.
Hormone Therapy and Risk of Myocardial Infarction : A National Register Study
TLDR
These data did not show any overall association between HT and risk of MI among older women who currently used HT; increased risk was found in younger women; and longer duration of HT also increased the risk among younger women, but not older women.
Long term hormone therapy for perimenopausal and postmenopausal women.
TLDR
Assessment of the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life found no statistically significant benefits.
Menopausal Hormone Therapy and Mortality: A Systematic Review and Meta-Analysis.
TLDR
The current evidence suggests that MHT does not affect the risk of death from all causes, cardiac death and death from stroke or cancer, whereas estrogen use was not associated with mortality of other types of cancer.
Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study
TLDR
The use of transdermal HRT containing low doses of oestrogen does not seem to increase the risk of stroke, and the presence of residual confounding cannot be entirely excluded in the interpretation of this finding.
Hormone Therapy and Ovarian Cancer
TLDR
It is concluded that HT increases the risk of ovarian cancer with slight effect on risk of different routes of administration, regimens, progestin types, length of use, and doses.
Vaginal estradiol use and the risk for cardiovascular mortality.
TLDR
The use of VE was accompanied by decreases in the risk for CHD and stroke death, and in 1000 women using VE for up to 10 years, a maximum of 24 fewer CHD deaths and 18 fewer stroke deaths is likely to occur.
Observational Studies Analyzed Like Randomized Experiments: An Application to Postmenopausal Hormone Therapy and Coronary Heart Disease
TLDR
The findings suggest that the discrepancies between the Women's Health Initiative and Nurses’ Health Study ITT estimates could be largely explained by differences in the distribution of time since menopause and length of follow-up.
Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis.
TLDR
Observational evidence warranting low confidence suggests that compared to transdermal ET, oral ET may be associated with increased risk of VTE and DVT, but not MI.
The effects of tibolone in older postmenopausal women.
TLDR
Tibolone reduced the risk of fracture and breast cancer and possibly colon cancer but increased therisk of stroke in older women with osteoporosis and the study was stopped at the recommendation of the data and safety monitoring board.
...
1
2
...